DNA topoisomerase I (Top1p) catalyzes changes in DNA topology via the formation of an enzyme-DNA covalent complex that is reversibly stabilized by the antitumor drug, camptothecin (CPT). During S-phase, collisions with replication forks convert these complexes into cytotoxic DNA lesions that trigger cell cycle arrest and cell death. To investigate cellular responses to CPT-induced DNA damage, a yeast genetic screen identified conditional tah mutants with enhanced sensitivity to self-poisoning DNA topoisomerase I mutant (Top1T722Ap), which mimics the action of CPT. Mutant alleles of three genes, DOA4, SLA1 and SLA2, were recovered. A nonsense mutation in DOA4 eliminated the catalytic residues of the Doa4p deubiquitinating enzyme, yet retained the rhodanase domain. At 36°C, this doa4-10 mutant exhibited increased sensitivity to CPT, osmotic stress, and hydroxyurea, and a reversible petite phenotype. However, the accumulation of pre-vacuolar class E vesicles that was observed in doa4⌬ cells was not detected in the doa4-10 mutant. Mutations in SLA1 or SLA2, which alter actin cytoskeleton architecture, induced a conditional synthetic lethal phenotype in combination with doa4-10 in the absence of DNA damage. Here actin cytoskeleton defects coincided with the enhanced fragility of large-budded cells. In contrast, the enhanced sensitivity of doa4-10 mutant cells to Top1T722Ap was unrelated to alterations in endocytosis and was selectively suppressed by increased dosage of the ribonucleotide reductase inhibitor Sml1p. Additional studies suggest a role for Doa4p in the Rad9p checkpoint response to Top1p poisons. These findings indicate a functional link between ubiquitin-mediated proteolysis and cellular resistance to CPT-induced DNA damage.DNA topoisomerases catalyze changes in the linkage of DNA strands, allowing for DNA unwinding or decatenation during DNA replication, transcription, recombination, and chromosome segregation (1, 2). Eukaryotic DNA topoisomerase I (Top1p) transiently cleaves a single strand of duplex DNA and forms a covalent tyrosyl linkage with a 3Ј-phosphoryl DNA end. The covalent Top1p-DNA intermediate allows for DNA rotation while conserving the energy of the cleaved phosphodiester bond.DNA topoisomerase I is the cellular target of the antitumor drug, camptothecin (CPT), 1 which reversibly stabilizes the covalent Top1p-DNA complex by inhibiting DNA religation (3-5). The ternary CPT-Top1p-DNA complexes per se are insufficient to induce a cytotoxic response. Rather, collisions with advancing replication forks convert the drug-stabilized complexes into the irreversible DNA lesions that trigger cell cycle arrest and cell death. This model is consistent with the S-phase specificity of CPT and the observation that inhibition of DNA synthesis by aphidicolin abrogates the cytotoxic action of the drug (6).In the yeast Saccharomyces cerevisiae, DNA topoisomerase